Intratumour variation of biomarker expression by immunohistochemistry in resectable non-small cell lung cancer

European Journal of Cancer

Volumn 49, Issue 11, 2013, Pages 2494-2503

  Jakobsen, Jan Nyrop ^a   Santoni Rugiu, Eric ^a   Ravn, Jesper ^a   Sørensen, Jens Benn ^a  

^a Rigshospitalet   (Denmark)

Author keywords

Biomarker; Chemotherapy; EGFR; ERCC1; Immunohistochemistry; Ki 67; NSCLC; RRM1; Thymidylate synthase; TUBB 3

Indexed keywords

BETA TUBULIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; KI 67 ANTIGEN; RIBONUCLEOTIDE REDUCTASE; RIBONUCLEOTIDE REDUCTASE M1; THYMIDYLATE SYNTHASE; UNCLASSIFIED DRUG;

ARTICLE; CELL HETEROGENEITY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG SMALL CELL CANCER; LYMPH NODE METASTASIS; MALE; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; TUMOR VOLUME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR MARKERS, BIOLOGICAL;

EID: 84879303713     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2013.04.003     Document Type: Article

References (21)

1. T.S. Mok, Y.L. Wu, and S. Thongprasert Gefitinib or carboplatin- paclitaxel in pulmonary adenocarcinoma N Engl J Med 361 2009 947 957
2. E.L. Kwak, Y.J. Bang, and D.R. Camidge Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer N Engl J Med 363 2010 1693 1703
3. G. Scagliotti, N. Hanna, and F. Fossella The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies Oncologist 14 2009 253 263
4. K.A. Olaussen, A. Dunant, and P. Fouret DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy N Engl J Med 355 2006 983 991
5. A.C. Vilmar, E. Santoni-Rugiu, and J.B. Sørensen Class III β-tubulin in advanced NSCLC of adenocarcinoma subtype predicts superior outcome in a randomized trial Clin Cancer Res 17 2011 5205 5214
6. K. Takezawa, I. Okamoto, and W. Okamoto Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer Br J Cancer 104 2011 1594 1601
7. J.J. Lee, C.H. Maeng, and S.K. Baek The immunohistochemical overexpression of ribonucleotide reductase regulatory subunit M1 (RRM1) protein is a predictor of shorter survival to gemcitabine-based chemotherapy in advanced non-small cell lung cancer (NSCLC) Lung Cancer 70 2010 205 210
8. R. Nishimura, T. Osako, and Y. Okumura Clinical significance of Ki-67 in neoadjuvant chemotherapy for primary breast cancer as a predictor for chemosensitivity and for prognosis Breast Cancer 17 2010 269 275
9. R. Pirker, J.R. Pereira, and J. von Pawel EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study Lancet Oncol 13 2012 33 42
10. J.P. Pignon, H. Tribodet, and G.V. Scagliotti Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group J Clin Oncol 26 2008 3552 3559
11. C. Coghlin, and G.I. Murray Current and emerging concepts in tumour metastasis J Pathol 222 2010 1 15
12. V. Almendro, A. Marusyk, and K. Polyak Cellular Heterogeneity and Molecular Evolution in Cancer Annu Rev Pathol 24 2012 277 302
13. C.M. Choi, S.C. Yang, and H.J. Jo Proteins involved in DNA damage response pathways and survival of stage I non-small-cell lung cancer patients Ann Oncol 23 2012 2088 2093
14. K. Kaira, T. Takahashi, and H. Murakami The role of βIII-tubulin in non-small cell lung cancer patients treated by taxane-based chemotherapy Int J Clin Oncol 2012
15. A.C. Vilmar, E. Santoni-Rugiu, and J.B. Sørensen ERCC1 and histopathology in advanced NSCLC patients randomized in a large multicenter phase III trial Ann Oncol 21 2010 1817 1824
16. A. Vilmar, E. Santoni-Rugiu, and J.B. Sørensen ERCC1, toxicity and quality of life in advanced NSCLC patients randomized in a large multicentre phase III trial Eur J Cancer 46 2010 1554 1562
17. W.D. Travis, E. Brambilla, and M. Noguchi International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: international multidisciplinary classification of lung adenocarcinoma: executive summary Proc Am Thorac Soc 8 2011 381 385
18. A.C. Vilmar, E. Santoni-Rugiu, and J.B. Sorensen Predictive impact of RRM1 protein expression on vinorelbine efficacy in NSCLC patients randomly assigned in a chemotherapy phase III trial Ann Oncol 2012
19. K. Taniguchi, J. Okami, and K. Kodama Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib Cancer Sci 99 2008 929 935
20. L. Taillade, F. Penault-Llorca, and T. Boulet Immunohistochemichal expression of biomarkers: a comparative study between diagnostic bronchial biopsies and surgical specimens of non-small-cell lung cancer Ann Oncol 18 2007 1043 1050
21. J.N. Jakobsen, and J.B. Sørensen Clinical impact of ki-67 labeling index in non-small cell lung cancer Lung Cancer 79 2012 1 7